Active immunization against murine TNFα peptides in mice: Generation of endogenous antibodies cross-reacting with the native cytokine and in vivo protection

Vaccine

Volumn 22, Issue 23-24, 2004, Pages 3144-3153

  Capini, C J ^a,g   Bertin Maghit, S M ^a,g   Bessis, N ^b   Haumont, P M ^a   Bernier, E M ^a   Muel, E G ^a   Laborie, M A ^a   Autin, L ^c   Paturance, S ^d   Chomilier, J ^c   Boissier, M C ^b   Briand, J P ^e   Muller, S ^e   Cavaillon, J M ^f   Therwath, A ^g   Zagury, J F ^a,g  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c UNIVERSITÉ PIERRE ET MARIE CURIE   (France)

^d CNRS   (France)

^e INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^f INSTITUT PASTEUR   (France)

^g Lab d'Oncologie Moléculaire   (France)

Author keywords

Antibodies; Autoimmune disease; Cytokine; Immunization; Peptide

Indexed keywords

CYTOKINE; GALACTOSAMINE; LIPOPOLYSACCHARIDE; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CROSS REACTION; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESEARCH; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMORAL IMMUNITY; INFECTION PREVENTION; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BLOCKING; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; CROSS REACTIONS; DRUG DESIGN; FEMALE; GALACTOSAMINE; LIPOPOLYSACCHARIDES; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; SHOCK; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3843101609     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.01.064     Document Type: Article

References (38)

1. Probert L., Akassoglou K., Kassiotis G., Pasparakis M., Alexopoulou L., Kollias G. TNF alpha transgenic and knockout models of CNS inflammation and degeneration. J. Neuroimmunol. 72:1997;137-141
2. Huang W.X., Huang P., Link H., Hillert J. Cytokine analysis in multiple sclerosis by competitive RT-PCR: a decreased expression of IL10 and a increased expression of TNF alpha in chronic progression. Mult. Scler. 5:1999;342-348
3. Green E.A., Flavell R.A. The temporal importance of TNF alpha expression in the development of diabetes. Immunity. 12:2000;459-469
4. Espersen G.T., Vestergaard M., Ernst E., Grunnet N. Tumour necrosis factor alpha and interleukin 2 in plasma from rhumatoid arthritis patients in relation to disease activity. Clin. Rheumatol. 10:1991;374-376
5. Leirisalo-Repo M., Paimela L., Jaattela M., Koskimies S., Repo H. Production of TNFa by monocytes of patients with early rhumatoid arthritis is increased. Scand. J. Rheumatol. 24:1995;366-371
6. Pfeffer K. Biological functions of tumor necrosis factor cytokines and theirs receptors. Cyto Growth Factor Rev. 14:2003;185-191
7. Meloni F. Tumor necrosis factor alpha. Biological aspects. G. Ital. Chemoiter. 36:1989;29-37
8. Favrot M., Combaret V., Blay J.Y., Capdeville R., Zhou D.C., Clapisson G., Chouaib S., Franks C.R., Philip T. TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2. Eur. Cytokine. Netw. 1:1990;221-227
9. Jones E.Y., Stuart D.I., Walker N.P. The structure of tumour necrosis factor - implications for biological function. J. Cel. Sci. Suppl. 13:1990;11-18
10. Azra Raza. Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis and myelodysplastic syndromes. Microsc. Res. Tech. 50:2000;229-235
11. Jones R.E., Moreland L.W. Tumor necrosis factor inhibitors for rheumatoid arthritis. Bull. Rheum. Dis. 48:1999;1-4
12. Intercepting TNF alpha with Etanercept to treat arthritis. Drug. Ther. Perspect. 14 (1999) 1-5.
13. Moreland L.W., Schiff M.H., Baumgartner S.W., Tindall E.A., Fleischmann R.M., Bulpitt K.J., et al. Etanercept therapy in rhumatoid arthritis, a randomized, controlled trial. Ann. Intern. Med. 130:1999;478-486
14. Fiers W., Brouckaert P., Goldberg A.L., Kettelhut I., Suffys P., Tavernier J., et al. Strucuture-function relationship of tumor necrosis factor and its mechanism of action. Ciba. Found. Symp. 131:1987;109-123
15. Zagury D., Le Buanec H., Bizzini B., Burny A., Lewis G., Gallo R.C. Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseases. Cytokine Growth Factor Rev. 14:2003;123-137
16. Keane J., Gershon Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 345:2001;1098-1104
17. Dalum I., Butler D.M., Jensen M.R., Hindersson P., Steinaa L., Waterston A.M., et al. Therapeutic antibodies elicited by immunization against TNFα Nat. Biotechnol. 17:1999;666-670
18. Dalum I., Jensen M.R., Hindersson P., Elsner H.I., Mouritsen S. Breaking of B cell tolerance toward a highly conserved self protein. J. Immunol. 157:1996;4796
19. Dalum I., Jensen M.R., Gregorius K., Thomasen C.M., Elsner H.I., Mouritsen S. Induction of cross-reactive antibodies against a self protein by immunization with a modified self protein containing a foreign T helper epitope. Mol. Immunol. 34:1997;1113
20. Wildbaum G., Youssef S., Karin N. A targeted DNA vaccine augments the natural immune response to self TNF-alpha and suppresses ongoing adjuvant arthritis. J. Immunol. 165:2000;5860-5866
21. Richard M., Grencis R.K., Humphreys N.E., Renauld J.C., Van Snick J. Anti IL9 vaccination prevents worm expulsion and blood eosinophilia in Trichuris muris-infected mice. PNAS. 97:2000;767-772
22. Youssef S., Maor G., Wildbaum G., Grabie N., Gour-Lavie A., Karin N. C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis. J. Clin. Invest. 106:2000;361-371
23. Hertz M., Mahalingam S., Dalum I., Klysner S., Mattes J., Neisig A., et al. Active Immunization against IL5 bypasses immunological tolerance and ameliorates experimental asthma. J. Immunol. 167:2001;3792-3799
24. Zagury D., Lecoq H., Gervi I., Le Buanec H., Zagury J.F., Bizzini B., et al. Anti IFN alpha immunization raises the IFN alpha neutralizing capacity of serum - an adjuvant to antiretroviral tritherapy. Biomed. Pharmacother. 53:1999;90-92
25. Gringeri A., Musicco M., Hermans P., Bentwich Z., Cusini M., Bergamasco A., et al. Active anti-interferon alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1 - infected patients (the EURIS study). J. Acquir Immune Defic. Syndr. Hum. Retrovirol. 20:1999;358-370
26. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., et al. The Protein Data Bank. Nucleic Acids Res. 28:2000;235-242
27. Thomas EA, Production S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Antisera using peptide conjugates. Methods in molecular biology. Neuropeptide Protocols Z37, 553-555.
28. Amiot F., Fitting C., Tracey K.J., Cavaillon J.M., Dautry F. Lipopolysaccharide-induced cytokine cascade and lethality in LT alpha/TNF alpha-deficient mice. Mol. Med. 3:1997;864-875
29. Kim B.J., Kim M.S., Kim K.B., Kim K.W., Hong Y.M., Kim I.K., et al. Sensitizing effects of cadmium on TNF-alpha and TRAIL-mediated apoptosis of NIH3T3 cells with distinct expression patterns of p53. Carcinogenesis. 23:2002;1411-1417
30. Eck M.J., Sprang S.R. The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. J. Biol. Chem. 264:1989;17595-17605
31. Van Ostade X., Tavernier J., Prange T., Fiers W. Localization of the active site of human tumour necrosis factor (hTNF) by mutational analysis. EMBO J. 11:1991;3156
32. Tsujimoto M., Tanaka S., Sakuragawa Y., Tsuruoka N., Funakoshi K., Butsugan T., et al. Comparative studies of the biological activities fo human tumor necrosis factor and its derivatives. J. Biochem. 101:1987;919-925
33. Yamamoto R., Wang A., Vitt C.R., Lin L.S. Histidine 15: an important role in the cytotoxic activity of human tumor necrosis factor. Protein Eng. 2:1989;553-558
34. Menzies-Gow A., Flood-Page P., Sehmi R., Burman J., Hamid Q., Robinson D.S., et al. Anti-IL5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors en the Bronchial mucosa of atopic asthmatics. J. Allergy Clin. Immunol. 111:2003;714-719
35. Ghiara P., Boraschi D., Nencioni L., Ghezzi P., Tagliabue A. Enhancement of in vivo immune response by tumor necrosis factor. J. Immunol. 139:1987;3676-3679
36. Rodriguez C., Roldan E., Navas G., Brieva J.A. Essential role of tumor necrosis factor-alpha in the differentiation of human tonsil in vivo induced B cells capable of spontaneous and high-rate immunoglobulin secretion. Eur. J. Immunol. 23:1993;1160-1164
37. Scallon B., Cai A., Solowski N., Rosenberg A., Song X.Y., Shealy D., et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol. Exp. Ther. 301:2002;418-426
38. Oberholzer A., Oberholzer C., Bahjat F.R., Edwards C.K. 3rd, Moldawer L.L. Genetic determinants of lipopolysaccharide and D-galactosamine-mediated hepatocellular apoptosis and lethality. J. Endotoxin. Res. 7:2001;375-380